CPX-351 Liposomal Assay for Leukemia Treatment Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematological malignancies, such as acute myelogenous leukemia, are ineffective for certain patients due to the heterogeneity of cancers and the inefficacy of conventional nano-particulate drug formulations in ex vivo cytotoxicity testing, which often underpredicts in vivo success.
Innovation Solution
Developing a method to assess the cytotoxicity and uptake of CPX-351, a synergistic liposomal combination of daunorubicin and cytarabine, in ex vivo cell cultures from patients to predict treatment effectiveness, utilizing genetic and phenotypic markers like FLT-3, NPM-1, and CEBPα mutations to identify suitable candidates for CPX-351 treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional nano-particulate drug formulations are used for ex vivo cytotoxicity testing, then the testing process is simplified, but the test results underpredict in vivo success and lack reliability
Solution Approach 1:
The patent introduces flow cytometry as an intermediary measurement technique that detects intact liposome uptake by leukemia cells. This intermediary measurement serves as a reliable predictor of in vivo treatment success, bridging the gap between simple ex vivo testing and accurate treatment prediction. The flow cytometry assay measures cellular uptake of the liposomal formulation without requiring drug release, providing reliable predictive data while maintaining ex vivo simplicity.
2Ease of operation
If standard-of-care treatment is used for all leukemia patients, then treatment protocol is simplified, but treatment effectiveness is reduced due to cancer heterogeneity
Solution Approach 1:
The patent implements preliminary action by performing ex vivo flow cytometry testing on patient samples before initiating treatment. This preliminary assessment identifies which patients will respond to CPX-351 liposomal therapy versus standard-of-care, enabling personalized treatment selection. The test measures uptake of liposomes by leukemia cells in vitro, providing advance information to guide treatment decisions and improve effectiveness for heterogeneous patient populations.
3Reliability
If CPX-351 liposomal formulation is used, then treatment effectiveness is improved for responsive patients, but device complexity and treatment cost increase
Solution Approach 1:
The patent demonstrates universality by showing that the flow cytometry assay can evaluate multiple aspects of liposome-cell interaction simultaneously. The same measurement platform assesses uptake efficiency, cellular internalization, and predictive response to treatment. This multi-functional approach justifies the use of the complex liposomal formulation by providing comprehensive evaluation capabilities in a single assay system.
Data Source
AI summary
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.